EUCTR2014-001377-14-ES
Active, not recruiting
Not Applicable
A multicenter, single arm, phase II clinical trial of pimecrolimus administered topically to patients with Stages Ia-IIa mycosis fungoides. - Study PimTo-MF.
Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre0 sitesMay 8, 2014
ConditionsPatients with Stages Ia-IIa of Mycosis Fungoides.Therapeutic area: Diseases [C] - Cancer [C04]
DrugsElidel 10 mg/g crema
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with Stages Ia-IIa of Mycosis Fungoides.
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological diagnosis of Mycosis Fungoides (Stage IA\-IIA) confirmed by previous or current biopsy. If the previous biopsy was inconclusive, a confirmatory biopsy must be obtained before entering the study.
- •Willingness and ability to sign inform consent and sign it up.
- •Functional status according to the Eastern Cooperative Oncology Group (ECOG) of the subject between 0 and 1 at the screening visit.
- •Age ? 18 years.
- •An acceptable organic functional condition defined by certain hematological and biochemical values.
- •Women of childbearing potential must have a pregnancy test negative seven days before inclusion in the study.
- •Patients women and men married to women of childbearing potential must use contraception during the entire period of treatment and for one month afterwards. A non\-hormonal contraceptive treatment is also necessary for women who use hormonal measures. Men with female partners of childbearing age or pregnant women, patients must use condoms in sexual intercourse during the treatment period.
- •Breastfeeding women should discontinue nursing prior to treatment initiation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •Subjects with a history of other primary malignancies within 5 years prior or concomitant (except in situ cancer, basal cell carcinoma or squamous cell skin carcinoma, adequately treated).
- •Known or suspected hypersensitivity to treatment with tacrolimus or pimecrolimus.
- •No previous wash up of at least 1 month of any previous treatment unless patient is in progressive disease. In that case wash up should be at least 2 weeks.
- •Concurrent treatment for Mycosis Fungoides. Topical or systemic corticosteroids are strictly prohibited. It is not allowed concurrent use of other calcineurin inhibitors.
- •Patient not fully recovered from toxicity/adverse event secondary to any previous treatment.
- •Diagnosis of any serious intercurrent illness or infection at the time of entering the study, which may interfere with the study treatment.
- •Patients who are unable to apply, either by themselves or by their relatives or carers, the study investigational drug in the affected areas.
- •Known contraindication to pimecrolimus or its excipients.
- •Patienst must not have participated in another clinical trial in the 30 days prior to entry into this trial nor have participated in any other study with tacrolimus or pimecrolimus.
- •Diagnosis of active or chronic infection with HIV, HBV or HCV. Absence of any active infection.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GISTEUCTR2005-004837-16-DEovartis Pharma GmbH53
Recruiting
Not Applicable
A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumorJPRN-UMIN000026817PO Epidemiological and Clinical Research Information Network(ECRIN)55
Recruiting
Phase 2
A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.bone cancerchondrosarcoma10040778NL-OMON47217eids Universitair Medisch Centrum23
Active, not recruiting
Phase 1
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsEUCTR2013-005155-32-NLeiden University Medical Center108
Active, not recruiting
Phase 1
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsConventional chondrosarcomaMyxoid liposarcoma with PIK3CA mutation or PTEN lossMesenchymal or dedifferentiated chondrosarcomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-005155-32-ESGrupo Español de Investigación en Sarcomas (GEIS)